3 results
-
Proposed extension of the abbreviated procedure for new medicine applications and section 24(5)(a) notifications
This consultation is aimed at pharmaceutical companies seeking to submit abbreviated applications to Medsafe for regulatory approval of new medicine products or changed medicine notifications. Medsafe is seeking your feedback on changes to these guidelines: Guideline on the Regulation of Therapeutic Products in New Zealand: New Medicine Applications Guideline on the Regulation of Therapeutic Products in New Zealand: Changed Medicine Notifications and... MoreCloses 13 March 2026 -
Ngā Paerewa Health and Disability Services Standard consultation 2026
Ngā Paerewa Health and Disability Services Standard 2021 (Ngā Paerewa) came into effect in February 2022. Under the requirements of the Health and Disability Services (Safety) Act 2001 (the Act), a regular review of the Standard is required. Consultation The Ministry of Health invites organisations and individuals to give their feedback on the Standard and participate in a short consultation. The feedback received will help to determine whether any changes are needed to the... MoreCloses 16 March 2026 -
Verification Pathway for New Medicine Applications
This consultation is primarily aimed at pharmaceutical companies seeking to submit applications to Medsafe for new medicines for consent by verification. Consent by verification is the application pathway that enables expedited approval of medicines in New Zealand. This relies on assessment and approval by two recognised overseas regulatory authorities. The verification approval process was enabled by the Medicines Amendment Act 2025, and is described in section 22A to 22F of the Medicines... MoreCloses 10 April 2026
3 results.
Page 1 of 1